Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a mo… Read more
Kiniksa Pharmaceuticals Ltd (KNSA) - Net Assets
Latest net assets as of September 2025: $535.38 Million USD
Based on the latest financial reports, Kiniksa Pharmaceuticals Ltd (KNSA) has net assets worth $535.38 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($712.33 Million) and total liabilities ($176.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $535.38 Million |
| % of Total Assets | 75.16% |
| Annual Growth Rate | N/A |
| 5-Year Change | 40.55% |
| 10-Year Change | N/A |
| Growth Volatility | 49.76 |
Kiniksa Pharmaceuticals Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Kiniksa Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kiniksa Pharmaceuticals Ltd (2016–2024)
The table below shows the annual net assets of Kiniksa Pharmaceuticals Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $438.44 Million | -0.09% |
| 2023-12-31 | $438.84 Million | +10.78% |
| 2022-12-31 | $396.15 Million | +114.09% |
| 2021-12-31 | $185.04 Million | -40.68% |
| 2020-12-31 | $311.94 Million | +38.38% |
| 2019-12-31 | $225.42 Million | -19.28% |
| 2018-12-31 | $279.27 Million | +411.31% |
| 2017-12-31 | $-89.71 Million | -248.62% |
| 2016-12-31 | $-25.73 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kiniksa Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 49501800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $20.00K | 0.00% |
| Other Comprehensive Income | $-163.00K | -0.04% |
| Other Components | $959.72 Million | 218.90% |
| Total Equity | $438.44 Million | 100.00% |
Kiniksa Pharmaceuticals Ltd Competitors by Market Cap
The table below lists competitors of Kiniksa Pharmaceuticals Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Songcheng Performance Develop
SHE:300144
|
$1.64 Billion |
|
Red Cat Holdings Inc
NASDAQ:RCAT
|
$1.64 Billion |
|
Forvia SE
PA:FRVIA
|
$1.64 Billion |
|
BillionToOne, Inc. Class A Common Stock
NASDAQ:BLLN
|
$1.64 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
$1.64 Billion |
|
XiaMen HongXin Electron-tech Co Ltd
SHE:300657
|
$1.63 Billion |
|
Guizhou Chanhen Chemical Corp
SHE:002895
|
$1.63 Billion |
|
CompoSecure, Inc.
NYSE:CMPO
|
$1.63 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kiniksa Pharmaceuticals Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 438,839,000 to 438,436,000, a change of -403,000 (-0.1%).
- Net loss of 43,193,000 reduced equity.
- Share repurchases of 4,984,000 reduced equity.
- Other comprehensive income decreased equity by 169,000.
- Other factors increased equity by 47,943,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-43.19 Million | -9.85% |
| Share Repurchases | $4.98 Million | -1.14% |
| Other Comprehensive Income | $-169.00K | -0.04% |
| Other Changes | $47.94 Million | +10.94% |
| Total Change | $- | -0.09% |
Book Value vs Market Value Analysis
This analysis compares Kiniksa Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.58x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-0.79 | $46.50 | x |
| 2017-12-31 | $-2.76 | $46.50 | x |
| 2018-12-31 | $-6.57 | $46.50 | x |
| 2019-12-31 | $4.17 | $46.50 | x |
| 2020-12-31 | $5.04 | $46.50 | x |
| 2021-12-31 | $2.70 | $46.50 | x |
| 2022-12-31 | $5.63 | $46.50 | x |
| 2023-12-31 | $6.10 | $46.50 | x |
| 2024-12-31 | $6.14 | $46.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kiniksa Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10.21%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 1.32x
- Recent ROE (-9.85%) is above the historical average (-18.80%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-21.40 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-55.90 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-83.80 Million |
| 2019 | -71.81% | 0.00% | 0.00x | 1.13x | $-184.41 Million |
| 2020 | -51.74% | -2094.77% | 0.02x | 1.12x | $-192.57 Million |
| 2021 | -85.35% | -409.72% | 0.17x | 1.26x | $-176.43 Million |
| 2022 | 46.29% | 83.28% | 0.48x | 1.16x | $143.75 Million |
| 2023 | 3.21% | 5.21% | 0.51x | 1.20x | $-29.80 Million |
| 2024 | -9.85% | -10.21% | 0.73x | 1.32x | $-87.04 Million |
Industry Comparison
This section compares Kiniksa Pharmaceuticals Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $580,491,146
- Average return on equity (ROE) among peers: -45.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kiniksa Pharmaceuticals Ltd (KNSA) | $535.38 Million | 0.00% | 0.33x | $1.64 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $14.78 Million | -64.19% | 0.99x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-241.47K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -329.21% | 0.78x | $194.64 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $37.06 Million | 39.05% | 0.16x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $32.70 Million | -18.88% | 0.16x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.84 |
| Adcock Ingram Holdings Limited (AIHLF) | $4.54 Billion | 14.90% | 0.58x | $85.61 Million |